非小细胞肺癌患者PD-L1表达与肿瘤突变负荷的个体内变异及其对免疫检查点抑制剂治疗结局的影响
该研究纳入具有多次PD-L1肿瘤比例评分和/或肿瘤突变负荷检测的非小细胞肺癌患者,分析402对PD-L1样本和413对TMB样本。PD-L1一致性中等(ρ=0.53,P<0.0001),TMB一致性高(ρ=0.80,P<0.0001)。尽管存在个体内一致性,生物标志物变异可影响免疫检查点抑制剂结局,作者认为在可行时于免疫检查点抑制剂启动前考虑重新评估。
要点
- PD-L1样本对一致性中等(ρ=0.53,P<0.0001),TMB样本对一致性高(ρ=0.80,P<0.0001)。
- PD-L1大幅升高(ΔTPS≥+50%)和降低(ΔTPS≤-50%)分别见于9.7%和8.0%的病例。
- 免疫检查点抑制剂前最近一次TMB≥10 mut/Mb者较<10 mut/Mb者PFS和OS改善。
核心结论
- 尽管PD-L1和TMB存在个体内一致性,这些生物标志物的变异可影响免疫检查点抑制剂结局,作者认为在可行时于免疫检查点抑制剂启动前考虑重新评估。
研究设计与样本
- 纳入具有多次PD-L1肿瘤比例评分和/或TMB评估的非小细胞肺癌患者,分析临床病理和基因组数据。
- 共纳入402对PD-L1样本对和413对TMB样本对。
主要发现
- PD-L1样本对间一致性中等(ρ=0.53,P<0.0001),TMB样本对间一致性高(ρ=0.80,P<0.0001)。
- 活检间隔时间较短与PD-L1一致性较高相关,但与TMB一致性无关。
- PD-L1大幅升高(ΔTPS≥+50%)和大幅降低(ΔTPS≤-50%)分别见于9.7%和8.0%的病例。
- PD-L1(而非TMB)在中间接受免疫检查点抑制剂后降低(P=0.02)。
- CD274、PDCD1LG2和JAK2的获得性拷贝数丢失与PD-L1大幅降低相关(q<0.05)。
关键数值与推荐
- 在免疫检查点抑制剂前有多次PD-L1评估的患者中,所有样本PD-L1≥1%的病例较至少一个样本PD-L1<1%且另一个样本PD-L1≥1%的病例,客观缓解率和无进展生存期改善。
- 在免疫检查点抑制剂前至少一个PD-L1<1%且一个≥1%的患者中,最近一次样本PD-L1≥1%的病例较最近一次PD-L1<1%的病例,中位无进展生存期更长。
- 在免疫检查点抑制剂前有多次TMB评估的患者中,基于最近一次评估TMB≥10 mut/Mb者较TMB<10 mut/Mb者,免疫检查点抑制剂的无进展生存期和总生存期改善;而基于最早一次TMB评估分类时未观察到差异。
临床怎么用
- 作者认为,尽管PD-L1和TMB存在个体内一致性,这些生物标志物的变异可影响免疫检查点抑制剂结局,在可行时于免疫检查点抑制剂启动前考虑重新评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed death receptor ligand 1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden (TMB) are key predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in non-small-cell lung cancer (NSCLC). Data on their variation across multiple samples are limited. PATIENTS AND METHODS: Patients with NSCLC and multiple PD-L1 TPS and/or TMB assessments were included. Clinicopathologic and genomic data were analyzed according to PD-L1 and TMB variation. RESULTS: In total, 402 PD-L1 sample pairs and 413 TMB sample pairs were included. Concordance between pairs was moderate for PD-L1 (ρ = 0.53, P < 0.0001) and high for TMB (ρ = 0.80, P < 0.0001). Shorter time between biopsies correlated with higher concordance in PD-L1, but not in TMB. Major increases (ΔTPS ≥ +50%) and decreases (ΔTPS ≤ -50%) in PD-L1 were observed in 9.7% and 8.0% of cases, respectively. PD-L1, but not TMB, decreased with intervening ICI (P = 0.02). Acquired copy number loss of CD274, PDCD1LG2, and JAK2 were associated with major decrease in PD-L1 (q < 0.05). Among patients with multiple PD-L1 assessments before ICI, cases where all samples had a PD-L1 ≥1%, compared to cases with at least one sample with PD-L1 <1% and another with PD-L1 ≥1%, achieved improved objective response rate and progression-free survival (PFS). Among patients with at least one PD-L1 <1% and one ≥1% before ICI, cases where the most proximal sample was PD-L1 ≥1% had longer median PFS compared to cases where the most proximal PD-L1 was <1%. Among patients with multiple TMB assessments before ICI, patients with a TMB ≥10 mut/Mb based on the most recent assessment, as compared to those with a TMB <10 mut/Mb, achieved improved PFS and overall survival to ICI; instead, no differences were observed when patients were categorized using the oldest TMB assessment. CONCLUSIONS: Despite intrapatient concordance in PD-L1 and TMB, variation in these biomarkers can influence ICI outcomes, warranting consideration for reassessment before ICI initiation when feasible.
引用
- Di Federico A, Alden SL, Smithy JW, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024. PMID: 38950679. doi:10.1016/j.annonc.2024.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。